Breakout results
Growth on every line at once: revenue up more than 20%, profit up more than 25% and margins expanding — all three in the same results filing, inside the window. One growth number is common; all three together is the bar. The mirror view holds the companies shrinking on every line in the same period.
| Company | Why it’s here — the filing | Reaction 1d / 1w / 1m | Price | Mcap |
|---|---|---|---|---|
| Financial Results for the qtr and year ended on March 31, 2026 | -3.6% -0.6% +0.6% | ₹1.43 | 78 Cr | |
| Outcome of the Board Meeting dated 25th May 2026 | +1.3% +2.9% +5.8% | ₹46.71 | 64,109 Cr | |
| Outcome of the Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III of the said Regulations | -4.7% -6.8% -14.2% | ₹163 | 170 Cr | |
| Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. | -2.3% -4.6% -2.9% | ₹8,597 | 2.28 L Cr |
A company appears when an NSE/BSE filing inside the last 90 days carries one of these classifier signals (minimum importance: Medium): Revenue Growth 20pct, Pat Growth 25pct, Ebitda Margin Expansion. Each row shows the latest qualifying filing; the reaction columns are the stock’s measured move 1 day, 1 week and 1 month after that filing.
MarketPing publishes facts, filings and measured history only — nothing on this page is investment advice, a recommendation or a rating.